Flow cytometry analysis further revealed that combined therapy significantly increased the frequency of MECA-79+ TA-HECs and MECA-79+CD62P+ TA-HECs (Figures 6I and 6J) and tumor infiltration of Tbet+ICOS+ Th1-like CD4+ T cells and CD8+ T cells (Figures 6K–6M). The gene discussed is CD4; the disease is neoplasm.